Jazz Pharmaceuticals Reprices and Extends Term Loan to May 2033

What Happened
Jazz Pharmaceuticals (through subsidiary Jazz Financing Lux S.à r.l.) filed an 8‑K on September 23, 2026 announcing Amendment No. 4 to its credit agreement that converts outstanding Tranche B‑2 Dollar Term Loans into a new Tranche B‑3, extends the maturity date and reduces the borrowing margin. The amendment amends the Amended Credit Agreement (originally dated May 5, 2021) and resets the maturity to May 5, 2033.

Key Details

• Tranche conversion and amounts: Outstanding Tranche B‑2 loans immediately prior to the amendment and outstanding Tranche B‑3 loans immediately after each totaled $1,895,000,000. Jazz Lux also borrowed an additional $273,310,355.18 of Tranche B‑3 to repay non‑converted B‑2 loans.
• New maturity: extended from May 5, 2028 to May 5, 2033.
• Interest repricing: Tranche B‑3 pays either Term SOFR or prime plus an applicable margin. Margins were reduced by 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime borrowings. Term SOFR has a floor of 0.50%; no credit spread adjustment applies.
• Amortization: quarterly payments equal to 0.25% of the initial principal, with the remaining balance due at final maturity. Material terms (security, covenants, events of default) remain substantially the same.

Why It Matters
This amendment pushes out the company’s near‑term debt maturity by five years and lowers the borrowing margin, which can reduce interest expense and ease near‑term refinancing pressure. Investors should note the sizable principal outstanding (~$1.895 billion) and the modest scheduled amortization (0.25% quarterly), leaving most principal due at the extended maturity. Security, covenants and default terms remain largely unchanged, so the company’s credit structure is preserved while improving liquidity/timing for future capital planning.